K-RAS and P53 Mutations in Association with COX-2 and Htert Expression and Clinico-Pathological Status of Nsclc Patients
We evaluated the occurrence of mutations in P53, K-RAS, COX-2, expression of COX-2 and hTERT and relations among clinicopathological signs. P53 mutations were identified in 34.4% of tumours, the majority of them occurring in SCC (squamous cell carcinoma, 55.6%). K-RAS was mutated in 12.2% of NSCLC t...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2008-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2008/232743 |
Summary: | We evaluated the occurrence of mutations in P53, K-RAS, COX-2, expression of COX-2 and hTERT and relations among clinicopathological signs. P53 mutations were identified in 34.4% of tumours, the majority of them occurring in SCC (squamous cell carcinoma, 55.6%). K-RAS was mutated in 12.2% of NSCLC tumours, the majority of the mutations being found in ADC (adenocarcinoma, 27.0%). Mutational screening detected three different COX-2 mutations and five different P53 mutations, published for the first time. With RT-PCR we observed that the expression of the tested genes, hTERT and COX-2, was highly significant for ADC (p < 0.01) and SCC (p < 0.05). Statistical analysis of the combined results revealed significant
correlation between expression of COX-2 and hTERT (p < 0.001), hTERT expression and staging (p < 0.05) and survival (p <
0.01). A positive correlation between COX-2 expression and K-RAS mutation (p <0.05) was also observed. This study provides
insight into associations between the analysed biomarkers and the clinical-pathological data of the patients. |
---|---|
ISSN: | 0278-0240 1875-8630 |